IL-7 |
|
Vaxjo ID |
255 |
|
Vaccine Adjuvant Name |
IL-7 |
|
Alternative Names |
Interleukin-7 |
|
Adjuvant VO ID |
VO_0001299
|
|
Description |
IL-7 is a cytokine that promotes T-cell survival and proliferation, particularly of naive and memory CD4⁺ and CD8⁺ T cells. It promotes a Th1-biased immune response, enhances effector T-cell infiltration into tumors, and reduces Tregs within the tumor microenvironment . |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
IL-7/IL-7R signaling is critical for development, maturation, maintenance and survival of many lymphocytes in the thymus and periphery |
|
Structure |
IL-7 is a small, soluble cytokine; here delivered using an injectable thermosensitive chitosan hydrogel for sustained release |
|
Molecular Weight |
Approx. 17.4 kDa |
|
Preparation |
Recombinant IL-7 was mixed with chitosan-based hydrogel and injected intratumorally |
|
Dosage |
2 μg IL-7 per injection, given intra-tumorally in B16 melanoma-bearing mice |
|
Function |
IL-7/IL-7R signaling is critical for development, maturation, maintenance and survival of many lymphocytes in the thymus and periphery. |
|
Safety |
Well tolerated in vivo; no systemic toxicity reported in treated mice |
| Related Vaccine(s) |
|
| References |
Bekele et al., 2021: Bekele Y, Sui Y, Berzofsky JA. IL-7 in SARS-CoV-2 Infection and as a Potential Vaccine Adjuvant. Frontiers in immunology. 2021; 12; 737406. [PubMed: 34603318].
|
